Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $216 |
| Triangulated Fair Value | $186 |
| 12-mo Scenario PWEV | $195 |
| Implied Return | -14% |
| Forward P/E | 15.5x |
| Market Cap | $32B |
| 52-Week Range | $121 – $207 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Blockbuster / Pipeline Re-Rate' (8% weight) — targets $346, +60% vs spot. It needs the multiple to hold or expand.
The dashboard below is the whole argument on one page: spot ($216) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' (20%) — targets $86, -60% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
P/E Multiple explains 68% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q1): management +0.36 vs analyst floor +0.00 → delta +0.36 (n=34 mgmt / 13 Q&A; 45th pctile across the S&P book, z -0.2).
Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q1 | +0.36 | +0.00 | +0.36 |
| 2025Q4 | +0.33 | +0.40 | -0.07 |
| 2025Q3 | +0.45 | +0.24 | +0.21 |
| 2025Q2 | +0.51 | +0.35 | +0.16 |
News (last 365d, 1000 articles): avg ticker sentiment +0.12 (bullish 12% / bearish 6%)
Scenario Analysis
The tree runs from a structural 'Structural — Patent Cliff (LOE) / IRA Pricing Erosion' downside ($86) to a 'Bull — Blockbuster / Pipeline Re-Rate' bull case ($346); the probability-weighted blend (PWEV $195) is -10% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Patent Cliff (LOE) / IRA Pricing Erosion | 20% | $86 | -60% |
| Pipeline Setback / Pricing Pressure | 17% | $146 | -32% |
| Base — Pipeline Offsets LOE | 35% | $203 | -6% |
| Growth — Launch / Indication Expansion | 20% | $274 | +27% |
| Bull — Blockbuster / Pipeline Re-Rate | 8% | $346 | +60% |
| Probability-Weighted (PWEV) | — | $195 | -10% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Patent Cliff (LOE) / IRA Pricing Erosion (20%, $86). Structural impairment — patent cliff (LOE) / IRA pricing erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 85.99; probability: 0.2.
- Pipeline Setback / Pricing Pressure (17%, $146). Cyclical downturn — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory weakens for 1–2 years before normalising. Drivers — implied_target: 146.03; probability: 0.17.
- Base — Pipeline Offsets LOE (35%, $203). Mid-cycle — normalised drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory; disciplined capital allocation; steady returns. Drivers — implied_target: 202.82; probability: 0.35.
- Growth — Launch / Indication Expansion (20%, $274). Upside — pipeline launches + indication expansion lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 273.81; probability: 0.2.
- Bull — Blockbuster / Pipeline Re-Rate (8%, $346). Upside tail — sustained tight conditions or a structural re-rate on pipeline launches + indication expansion. Drivers — implied_target: 345.81; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $176 | -19% |
| Peer P/E re-rate | multiple | $226 | +4% |
| Peer EV/Revenue re-rate | multiple | $445 | +106% |
| Scenario PWEV | multiple | $195 | -10% |
| DCF (5-year + terminal) | cash flow + terminal × | $173 | -20% |
| Triangulated (weighted) | — | $186 | -14% |
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $176 and 30% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (68% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 8.5%, 12x terminal FCF multiple → $173. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 16.16x) implies $226. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is tight (the methods corroborate one another).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Biopharma | $9.9B | 100% | 4% | 24% | 14x | 6% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory |
| net_debt_or_cash_b | -3.18 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.06 |
| div_yield | None |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | patent cliff (LOE) / IRA pricing erosion |
| upside | pipeline launches + indication expansion |
Industry Context — Health Pharma
This name sits in the Health Pharma as a biopharma. drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: LLY (biopharma) · JNJ (biopharma) · ABBV (biopharma) · MRK (biopharma) · AMGN (biopharma) · GILD (biopharma) · PFE (biopharma) · VRTX (biopharma) · BMY (biopharma) · REGN (biopharma) · BIIB (biopharma) · INCY (biopharma) · VTRS (biopharma)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Patent Cliff / IRA Pricing Erosion | 37% | 37% | |
| Mid-Cycle — Pipeline Offsets LOE | 35% | 35% | |
| Upside — Launches / Pipeline Re-Rate | 28% | 28% |
On the cluster's key downside — Patent Cliff / IRA Pricing Erosion () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_pharma cycle is the shared macro driver. Driver — drug pricing (IRA) + patent-cliff (LOE) exposure + pipeline/launch trajectory Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $10B | $2B | $1B | $1B | $2B | $2B |
| FY+2 | $11B | $3B | $1B | $1B | $2B | $2B |
| FY+3 | $11B | $3B | $1B | $1B | $2B | $2B |
| FY+4 | $11B | $3B | $1B | $1B | $2B | $2B |
| FY+5 | $12B | $3B | $1B | $1B | $2B | $2B |
| Terminal | — | — | — | — | $2B × 12x | $20B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 6% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.5% · Σ PV(FCF) $9B + PV(terminal) $20B = EV $29B; + net cash → equity $26B ÷ diluted shares 0.15B = $173/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $230/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 12% vs WACC 8% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| ABBV | 7.62x | 16.47x | 4% | 32% |
| AMGN | 6.33x | 15.85x | 4% | 34% |
| GILD | 5.66x | 15.22x | 4% | 39% |
| VRTX | 9.54x | 25.25x | 4% | 38% |
| Median | 6.975x | 16.16x | — | — |
Peer-median fwd P/E → $226; EV/Rev → $445.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $173 | 41% | $71 |
| Scenario PWEV | $195 | 29% | $57 |
| Monte Carlo median | $176 | 18% | $31 |
| Peer P/E | $226 | 12% | $27 |
| Triangulated | — | 100% | $186 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 8.4x | 10.2x | 12.0x | 13.8x | 15.6x |
|---|---|---|---|---|---|
| 6% | $146 | $168 | $190 | $212 | $234 |
| 8% | $139 | $160 | $181 | $202 | $223 |
| 8% | $133 | $153 | $173 | $193 | $214 |
| 10% | $128 | $147 | $166 | $185 | $204 |
| 10% | $122 | $140 | $159 | $177 | $195 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $132 | $142 | $153 | $163 | $174 |
| -1.5pp | $141 | $152 | $163 | $174 | $185 |
| +0.0pp | $150 | $162 | $173 | $185 | $197 |
| +1.5pp | $159 | $172 | $185 | $197 | $210 |
| +3.0pp | $169 | $183 | $196 | $210 | $223 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Op margin ±3pp | $150 | $197 | $47 |
| Revenue CAGR ±3pp | $153 | $196 | $43 |
| Terminal × ±15% | $153 | $193 | $40 |
| WACC ±1pp | $166 | $181 | $16 |
| FCF conversion ±10% | $173 | $173 | $0 |
Company lever — SoP/share vs Biopharma multiple (AI re-rating) (base 14x)
| Multiple | 9.8x | 11.9x | 14.0x | 16.1x | 18.2x |
|---|---|---|---|---|---|
| SoP/share | $634 | $775 | $915 | $1,055 | $1,196 |
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 12×, FY+5 revenue $12B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
The valuation is multiple-dependent (68% of variance); a de-rating toward the DCF anchor ($173) implies -20%.
Fact / Inference / Speculation
- FACT: Spot $216; 52-week range $121–$207; engine rating HOLD; base-case target $195 (-10%).
- INFERENCE: Triangulated FV $186 (-14%). P/E Multiple explains 68% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
- SPECULATION: At current prices the embedded bet is that the multiple holds or expands — P/E Multiple carries 68% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $186 (-14% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple (68% of variance) — fundamentally a multiple/regime call. SBC runs —M TTM (disclosed in the appendix).